Bora Group Posts Record 2Q26 Revenue and Strong Profits as Margins expand and Operations Resume Demand-Driven Growth

HONG KONG SAR - Media OutReach Newswire – 13 August 2026 – Bora Pharmaceuticals ("Bora"; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 2Q2026 and provides full year outlook update.

2Q26 Business and Financial Highlights

• Bora delivered historically record-high quarterly revenues of NT$5,889 million in 2Q26, up 47.2% quarter-over-quarter driven by broad-based operational momentum, with basic EPS of NT$4.36.
• CDMO revenue growth and increased site utilization rates, along with strong growth in the rare disease business and a return to growth for generics business of the Pharma Sales operations lifted group profitability, with gross margin expanding to 41.3% from 36.0% and operating margin reaching 16.8% from 10.2% in 1Q26. Excluding one-time costs related to the Weider Global Nutrition transaction, operating margin was approximately 18%.
• CDMO's strong backlog of US$317 million as of end of 2Q26, another historical high following a strong quarter, signals that Bora's core business continued to perform with higher demand.
• Pharma Sales' rare disease franchise continues to show double digit sequential growth and the increased demand from government channels during the quarter with stabilized pricing in DLS has lifted the generics business back to normal.
• Reflecting Bora's recent increase in investment in Sunway Biotech, from 35.97% to 42.27% and subsequent acquisitions of Weider Global Nutrition's, the Company has introduced "Consumer Healthcare (CHC)" as a new segment in its revenue mix disclosure beginning this quarter. In 2Q26, revenues from CHC were NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY, and contributed to 14% of the Bora Groups consolidated revenues, an all-time high.
• Cash-on-hand reached an all-time high of NT$8,431 million as the Company was preparing for MacroGenics Inc.'s Rockville facility acquisition.
• The Company has kicked off a group-wide AI in Manufacturing, BORA AIM, program aimed at improving process efficiency across sites, spanning engineering, quality and production. Bora has also signed a partnership with Insilico Medicine for AI drug discovery. The first 6 months will focus on beta version testing of the Bora AIM agents and AI champions to drive process consolidation.
• Share capital increased 0.3% during the quarter from employee stock option exercise.

Mr. Bobby Sheng, Chairman of Bora Group, stated, "We are pleased to announce Bora Group's return to strong operating profits and double to triple-digit growth on all key margins sequentially, as well as demonstrate that our soft 1Q26 performance was anomalous rather than structural. Our impressive sequential improvement was driven entirely by strong demand from both our CDMO and Pharma Sales businesses, with 2Q26 manufactured batches reaching 0.38 billion doses, led by increased commercial production in Maple Grove and Zhunan sites and a full quarter of operations in the Maryland injectable facility, while our flagship products DLS and VIGAFYDE® in Pharma Sales continues to secure leading market share.

Our focus right now is execution. CAPEX investments in our mature sites, including facilities in Taiwan and in Canada, continue to deliver operational leverage driven by gross margin expansion, and our recently acquired oral solid dose facility in Maple Grove continues to show stellar and impactful demand as we sign more projects. Our 12-month rolling backlog is at historic high in almost all our sites, despite projected manufacturing delays at our Maryland injectable facility as we diligently respond to FDA audit observations from a recent audit. Bora Group's commitment to the fast-growing Biologics manufacturing industry took another big step as we look to integrate 12,000 liters of capacity, and 3 commercial products from our Rockville facility, as well as see revenue recognition from this acquisition starting Q3. As Bora's CDMO footprint expands in the US, we continue to capture durable, high-value demand as customers increasingly prioritize supply security and onshore capacity.

In addition, we are seeing sustained growth and improved gross margins in the Vigabatrin franchise, our most important, rare disease franchise, thanks to renegotiations with our partner vendors. Accelerated state and government orders for generics products increased 2Q26 revenues and 6 new generics launches have also supported a more diversified generics portfolio. Together, the advancement in rare disease franchise and generics business has positioned Bora's Pharma Sales business, operating under the name Upsher-Smith, in a far stronger state than it was just a quarter ago.

As announced in July, we are excited to be developing a group-wide AI in Manufacturing program, BORA AIM, aimed at improving process efficiency across sites, spanning engineering, quality and production. We also announced a partnership with Insilico Medicine to enhance our understanding of AI drug discovery and create more customized AI manufacturing platforms for AIDD small molecules. In the next 12 months, Bora Group will be ready to showcase some exciting AI-enabled CDMO platforms that will truly add value to our partners and sharpen the overall competitive advantages of Bora Group.

As our momentum carries Bora into the second half of the year, we expect margins of our flagship products in Pharma Sales and CHC businesses to hold steady on continuous revenue growth, and improved efficiencies in the CDMO business in addition to consolidation of new revenues from the Rockville facility."

2Q26 Operational Achievements & 2026 Outlook

Global CDMO Operations

Revenues increased 30.3% year-over-year and 29.0% quarter-over-quarter including internal orders, and 33.0% and 40.2% external orders only, or NT$2,116.4 million. The growth was primarily driven by a strong rebound in injectables following the semi-annual maintenance in 1Q26 and same period last year, and demand acceleration overall as we continue to meet the increasing backlog.

CDMO business also signed a record high US$378.2 million in total external wins. Highlighted by a 10+2-year, multi product commercial contract in our Maple Grove facility with a new top-20 pharma company, and 14 new molecules from pre-commercial programs from multiple new customers. Bora is confident in its mid- to long-term growth trajectory as pharma and biotech companies continue to look for US based CDMOs as a part of their efforts to onshore US production and improve supply chain resilience.

During the quarter, 0.38 billion doses, or 109 molecules, were developed and manufactured. Contribution from the top 20 global pharmaceutical companies stood at roughly 30% and should increase drastically in the next 8 quarters.

Looking at 3Q26, the Company is highly optimistic, with our backlog having climbed to an unprecedented level even after a strong quarter of manufacturing output. We do anticipate some timing shifts in revenue recognition related to scheduled semi-annual maintenance at our Maryland injectable site, alongside targeted quality-enhancement activities in connection with observations on passive RABS (Restricted Access Barrier System) line received from an FDA audit that took place 2Q26. However, there has been no reduction in total commercial batch productions in 2026 as we speak and several existing clients have initiated transfers to the FlexPro isolator filling lines. RFP activity has risen, with the first GMP PPQ campaign starting in August. On the newest, isolator-based AST lines, factory acceptance testing (FAT) is planned for Q326, with qualification to follow in 2027, expanding our ability to onboard small-scale isolator programs, including tech transfers.

On biologics, Rockville facility revenue recognition started in the first month of 3Q26 and the site has confirmed that it is on track to deliver batch production volumes ahead of last year's run rate of around 13 batches for the remainder of 2026. We anticipate one-time transaction costs from this acquisition of approximately 3% of the purchase price including legal and FA fee and transition related expenses as stated in the Transition Service Agreement. The Rockville acquisition expands biologics capacity and brings integrated drug substance (DS) and drug product (DP) capabilities under one roof, strengthening our end-to-end service offering and attracting more inbound opportunities and higher value conversion with cross selling opportunities for our injectable business.

For our strategic investment in Tanvex Biopharma, the main Bora Biologics platform company, although the business still operates at a loss, Tanvex has built a strong presence in international conferences, especially Bio International in the US in June. We have seen a positive uptick in pipeline from leading biotechs and heavy weight biopharmas, and stable demand for early-stage PD programs in Zhubei. The Rockville acquisition is expected to orchestrate and accelerate opportunities for Tanvex in the coming quarters.

Pharma Sales Operations

Revenues decreased 2.7% year-over-year and increased 30.4% quarter-over-quarter, arriving at NT$2,934.04 million in 2Q26. The year-over-year decrease was mainly due to a product rationalization program in 2025 that lead to the withdrawal of a basket of legacy generics products.

During the quarter, specialty and brand came in strongly, up 58.8% for the quarter QoQ and displayed almost 50% growth against 2025 run rate. The rare-disease Vigabatrin franchise demand is robust, and our continuous investment in the segment has resulted in much broader patient access compared to when we acquired Upsher-Smith 28 months ago. On coverage, we are on track to achieve year-end formulary goal of >50%, supported by more regional plans and strong physician adoption as they gain experience with VIGAFYDE®. The Company has also renegotiated contracts with suppliers, leading to improved gross margins for the franchise during the quarter and expects full economic contribution starting 3Q26. Simultaneously, the Company out-licensed its non-core assets, Stiripentol generics and 505(b)(2), during the quarter, fully capturing the economic value of these drug assets to enable fueled and renewed focus on core specialty and brand business.

The generics business returned to stability as Upsher-Smith successfully defended flagship product DLS. High value generics advanced 20.6% sequentially from downstream restocking, narrowing the year-to-date YoY decline against 2025 run rate to high teens.

Having executed our way through specialty and brand business growth and generics portfolio optimization, we have returned to the 2023–2024 peaks of Pharma Sales performance but with healthier and more resilient operating profits. As of now, Upsher-Smith sees 6 ANDA pending approval.

CHC Operations

Bora Group has increased holdings of Sunway Biotech to 42.27% through a private placement at $NT 596 million. Subsequently, Sunway completed the acquisition of Weider Global Nutrition (WGN), a global nutritional supplements company with offices in the US, Spain, and Germany and products sold in over 60 countries. Benefitting from the consolidation of WGN that started in May, Consumer Health business totaled NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY. Focusing on longevity and sports nutrition, WGN's distribution strength is expected to meaningfully contribute to the CHC business in 2026 and beyond and shall deliver vertical-integration synergies to Sunway's existing ingredients' manufacturing operations. Together, the WGN acquisition is expected to catapult Sunway Biotech into a leading global nutritional supplements company and substantially accelerate top and bottom-line improvements in the future.

Recent Investor Conference

Bora will host English online earnings call at 8:00 a.m. Taiwan time on Aug. 14^th, 2026. The event will cover the Company's 2Q26 financial and business results and 2H26 outlook.

English Online Earnings Presentation Link: https://teams.microsoft.com/meet/225504163505748?p=UyyncWl1CnOzjBCNKD

Bora will participate in Goldman Sachs 2026 CDMO day in Singapore in Sept. For 1:1 meetings with management, please contact your GS representative.

Bora 2026 Earnings Schedule

Q3 2026: Expected in the 2^nd week of Nov 2026
Q4 2026: Expected in the 2^nd week of Mar 2027

Hashtag: #BoraGroup

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

HONG KONG SAR - Media OutReach Newswire - 13 August 2026 - FWD Hong Kong ("FWD") has released the results of its latest "Hong Kong Working Population Medical Protection Survey"², revealing a health protection gap among the working population. Among respondents with employer-provided group medical insurance, 71% stated that they primarily rely on this coverage, but only 29% believe their group medical coverage is sufficient to cover actual medical expenses. Only one in six individuals have purchased additional top-up protection plans for their group medical insurance to fill the gap (17%). Apart from insufficient coverage during employment, the survey also found that 74% of respondents worry about bearing high medical expenses alone after retirement, reflecting a general concern among the working population regarding the burden of medical expenses after leaving employment or retiring.

FWD survey: Over 70% of the workforce rely on group medical insurance, yet less than 30% find it sufficient to cover actual medical expenses

Kelvin Yu, Chief Proposition and Healthcare Officer, FWD Hong Kong & Macau, said: "The working population generally relies on group medical insurance provided by employers; however, the coverage may not be sufficient to cover the actual medical expenses of individuals and their families. As healthcare costs rise and career stages evolve, they may face significant protection gaps due to career transitions, leaving employment, or retirement. FWD Hong Kong's newly launched 'EBeyond Medical Insurance Solution' supports any group medical inpatient insurance scheme member^4,7 to top up their medical protection beyond their existing company medical insurance by answering just two simple health questions³. Existing members of FWD's group medical insurance schemes can even apply without health underwriting⁴. Through two flexible plan options, coupled with the first-in-market¹ conversion option, customers can seamlessly continue their medical protection through career transitions and into retirement. We continue to stand by our customer-led approach, commit to addressing customers' needs through innovative product design, redefining 'FWD The Next Standard'."

FWD has launched a new brand campaign, "FWD The Next Standard", to provide solutions for different customer pain points. The "EBeyond Medical Insurance Solution" is designed to address additional protection needs of group medical insurance scheme members, highlighting FWD's innovative protection philosophy of defining new standards.

Group medical coverage serves as first-line protection for the working population; concerns arise over its continuity with career transitions or leaving employment

FWD commissioned a survey of over 1,100 working individuals in Hong Kong aged between 25 and 65 from June to July this year. The survey results indicate that 64% of respondents would prioritise using their company group medical insurance when making medical claims. As the first-line protection for many working individuals, group medical coverage is generally tied to employment; when changing jobs, leaving employment, or retiring, the relevant protection will consequently terminate. Some group medical insurance scheme members purchase individual medical insurance with a deductible option to enhance protection while alleviating the premium burden. However, over half of them expressed that if they lose their group medical coverage in the future, they may not have the confidence to bear the relevant deductible alone (51%).

Furthermore, over 70% of respondents worry about bearing high medical expenses alone after retirement (74%), premiums becoming increasingly expensive as they age (74%), and medical inflation driving up healthcare costs (73%). More than two-thirds of respondents (68%) are concerned that applying for insurance at an older age will involve complicated underwriting procedures or even result in being declined.

Two plan options offering seamless protection continuity to group medical inpatient insurance scheme members, with no health underwriting or simple health underwriting only

FWD has newly launched the "EBeyond Medical Insurance Solution" ("EBeyond"), which is open to Eligible Group Medical Insurance Scheme(s)⁴ members. EBeyond offers two plan options that allow individuals to maintain continuous medical coverage when changing jobs, leaving employment or retiring, while catering to their protection needs at different life stages:

• EBoost Plan: Designed as a top-up to existing group medical insurance coverage during employment. It provides full coverage⁵ for major hospitalisation and surgical expenses (subject to the Annual Benefit Limit, Deductible⁶ and reimbursement percentage), expanding the health protection safety net.
• EBridge Plan: Tailored to serve as first-line protection for customers who lose their group medical coverage after career transitions or retirement. It offers four plan levels covering different ward classes, with optional supplementary major medical benefit ("SMM") for selected plan levels to further boost overall protection.

EBeyond also features the first-in-market¹ "first-dollar conversion option". After the policy has been in-force for two consecutive years from the policy date, the policy owner of an EBoost Plan can exercise this one-off option to convert to an EBridge Plan when their age next birthday is 45, 50, 55, 60 or 65. Without health underwriting of the insured person, the customer can shift the coverage to first-line medical protection to ensure coverage continuity after leaving employment or entering retirement.

EBeyond product features

• No health underwriting / Simple health underwriting:
  • Existing FWD group medical insurance scheme members⁴ can apply with no health underwriting;
  • Other eligible group medical insurance scheme members⁷ can apply by answering just two simple health questions³.
• Guaranteed lifetime Renewal⁸.
• Different protection options to match needs: The EBoost Plan and EBridge Plan offer three and four plan levels respectively, allowing flexible matching based on eligibility to apply, budget and existing company coverage levels.
• First-in-market¹ senior care and dementia support:
  • Features the "Dementia Support Programme". A designated support programme to the insured person or a referral service for a designated support programme to the parents of insured person upon the insured person's or the parents of insured person's first confirmed diagnosis of Alzheimer's Disease;
  • For insured persons age 51 (age next birthday), it offers an Alzheimer's Disease preventive care benefit, and provides an additional benefit for Alzheimer's Disease treatment;
  • For insured persons age 60 (age next birthday), it offers inpatient care services provided by a Healthcare Assistant⁹.
• Rewards for staying healthy and premium discount:
  • Enjoy up to 15% no claims premium discount¹⁰ upon renewal. After the policy has been in force for a designated period, expenses for travel, fitness or wellness course, or health check-up can be reimbursed¹¹.
  • From now until 30 September 2026, enjoy a 12-month premium discount when applying for the EBoost Plan¹².

• Existing FWD group medical insurance scheme members⁴ can apply with no health underwriting;
• Other eligible group medical insurance scheme members⁷ can apply by answering just two simple health questions³.

• Features the "Dementia Support Programme". A designated support programme to the insured person or a referral service for a designated support programme to the parents of insured person upon the insured person's or the parents of insured person's first confirmed diagnosis of Alzheimer's Disease;
• For insured persons age 51 (age next birthday), it offers an Alzheimer's Disease preventive care benefit, and provides an additional benefit for Alzheimer's Disease treatment;
• For insured persons age 60 (age next birthday), it offers inpatient care services provided by a Healthcare Assistant⁹.

• Enjoy up to 15% no claims premium discount¹⁰ upon renewal. After the policy has been in force for a designated period, expenses for travel, fitness or wellness course, or health check-up can be reimbursed¹¹.
• From now until 30 September 2026, enjoy a 12-month premium discount when applying for the EBoost Plan¹².

The "EBeyond Medical Insurance Solution" is underwritten by FWD Life Insurance Company (Bermuda) Limited (incorporated in Bermuda with limited liability) ("FWD"). The above information is for reference only, and does not contain the full terms and conditions and is subject to the policy provisions. For the exact terms and conditions, benefits, exclusions, key product risks and/or other details of the plan, please refer to the FWD website and the relevant product brochure: https://www.fwd.com.hk/files/v3/assets/blta9d684affff23c8c/blt08b9fb2c2ca1f183/EBeyond-Medical-Insurance-Solution-EN.pdf.

¹ Per a comparison made by FWD on 6 July 2026 among the medical plans of key insurers available in Hong Kong, the first-dollar conversion option, Golden years Hospital companion care, Additional benefit for Alzheimer's Disease treatment and Alzheimer's Disease preventive care benefit are first-in-market. The above statements are made by FWD based on currently available market information and its understanding thereof, and FWD shall not be liable for any errors or omissions.
² FWD commissioned ESDlife, a major lifestyle and health media platform in Hong Kong, to conduct the "Hong Kong Working Population Medical Protection Survey" from June to July 2026, interviewing 1,106 working individuals in Hong Kong aged between 25 and 65 via questionnaires.
³ Simple health questions are only available to eligible customers who satisfy the application requirements for simple health underwriting under the EBeyond Medical Insurance Solution. Where the EBeyond Medical Insurance Solution is offered under other campaigns or promotions with different application criteria or health underwriting arrangements, details of the relevant offers will be set out in the applicable promotional materials.
⁴ Eligible Group Medical Insurance Scheme(s) means group medical insurance schemes with hospitalisation benefits sold through FWD's distribution channels, including group medical insurance schemes underwritten by FWD Life Insurance Company (Bermuda) Limited (incorporated in Bermuda with limited liability) ("FWD") or Bolttech Insurance (Hong Kong) Company Limited ("Bolttech"), and other group medical insurance schemes approved by FWD. For the avoidance of doubt, group medical insurance schemes offering outpatient benefits only are not Eligible Group Medical Insurance Schemes. FWD reserves the right to change the definition of Eligible Group Medical Insurance Schemes from time to time at its sole discretion and without prior notice.
Eligible Member means a member (including an employee and his/her dependants) covered under an Eligible Group Medical Insurance Scheme who fulfils the applicable application criteria. Such criteria shall be determined by FWD from time to time at its sole discretion. The relevant eligibility criteria are set out in the "Enrollment Guidelines" section of this product brochure and are provided for reference only. FWD reserves the right to revise or amend any such criteria at its sole discretion and without prior notice.
⁵ Subject to the Annual Benefit Limit, reimbursement percentage and Deductible. Full cover means that no itemised benefit sublimit applies, the actual amount of Eligible Expenses and other expenses charged, after deducting the remaining Deductible (if any) and is subject to the Annual Benefit Limit, reimbursement percentage and the number of days limit (where applicable). Full cover applies to selected benefit items only, while other benefit items are not fully covered and are subject to respective benefit item's limits. Please refer to Benefit Schedule and Policy provisions for details. Full cover is limited to Reasonable and Customary charges or expenses incurred for services that are Medically Necessary. Please refer to the "Important Words" section for the definitions of "Medically Necessary" and "Reasonable and Customary" in Product Brochure.
⁶ Where requested by FWD upon submission of a claim, the Policy Owner or the Insured Person must declare whether the Insured Person is covered under any group medical scheme provided by other licensed insurance companies. Claims must first be made under such group medical policy (if any). Any unpaid portion of the Eligible Expenses and/or expenses may then be claimed under this Policy, subject to the Terms and Benefits of this Policy.
⁷ Other group medical insurance scheme members refer to individuals who meet the following eligibility requirements and declare that they satisfy such requirements:
a. Age Requirement:
i. Aged 56 or below (Age Next Birthday).
b. Applicable to Employees:
i. Must be currently actively employed and engaged in job duties, and must have been continuously employed for the most recent consecutive 12 months; and
ii. Must be currently covered under a group medical inpatient insurance plan and confirm that the group medical insurance card in his/her possession is valid and belongs to him/her.
c. Applicable to Employees' Children (Dependants):
i. Must be covered under the employee's group medical inpatient insurance plan and confirm that such coverage is valid; and
ii. Must be currently enrolled in and actively attending a mainstream kindergarten, primary school, secondary or university education programme at a recognised educational institution for a continuous period of 12 months.
iii. Subject to the successful approval of the employee's application.
This promotion is only applicable to apply for EBeyond Medical Insurance Solution – EBoost Plan during the promotion period from 27 July 2026 to 30 September 2026 (both dates inclusive) (policy must be issued on or before 30 November 2026).
⁸ Guaranteed yearly Renewal up to Age 101 (age next birthday), provided that the requirements set out in the renewal provisions of the Terms and Benefits of the Policy provisions are met.
⁹ Subject to the limits stated in the Benefit Schedule. This benefit is payable starting from the 3^rd day of Confinement.
¹⁰ If no claim has been made for 2 or more consecutive Policy Years immediately prior to Renewal, a discount will apply; a discount of up to 15% applies from 5 consecutive Policy Years onwards.
¹¹ Wellness joy benefit: Covers expenses for travel, a fitness or wellness course or a health check-up after the Policy has been in force for at least 2 consecutive years (applicable to Plans 3 and 4 under the EBridge Plan, and Plans B and C under the EBoost Plan) or 5 consecutive years (applicable to Plans 1 and 2 under the EBridge Plan, and Plan A under the EBoost Plan) from the Policy Date.
¹² The promotion period is from 6 July 2026 to 30 September 2026 (both dates inclusive) (policy must be issued on or before 31 October 2026) ("Promotion Period"). Eligible group medical insurance scheme members who successfully apply for EBeyond Medical Insurance Solution – EBoost Plan during the promotion period may be eligible for a 12-month premium discount in total in the first and second policy year.

Hashtag: #FWDHongKong

The issuer is solely responsible for the content of this announcement.

About FWD Hong Kong

FWD Hong Kong is part of the FWD Group (1828.HK), a pan-Asian life and health insurance business that serves approximately 40 million customers across 10 markets, including BRI Life in Indonesia. FWD Hong Kong is firmly positioned as a top five pan-Asian insurer by business scale in Hong Kong*.

FWD Hong Kong has been assigned strong financial ratings by international agencies. It offers life and medical insurance, employee benefits, and financial planning.

FWD's customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828.

For more information about FWD Hong Kong, please visit www.fwd.com.hk.

*According to Provisional Statistics on Hong Kong Long Term Insurance Business - January to December 2025, Insurance Authority of Hong Kong, as well as FWD's own assessment based on market information, FWD ranks among the top five pan-Asian insurers in Hong Kong in both new business first year premium and new business case count rankings. Calculated based on individual and group businesses. Pan-Asian insurers refer to multinational insurers currently having a well-established operation in the Asian market with multiple distribution channels.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **